DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Acute Liver Failure (ALF) Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Acute Liver Failure, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Acute Liver Failure Market

• The market size for Acute Liver Failure in the leading markets is expected to increase significantly by 2036.

• According to DelveInsight’s analysis, the total market size of ALF in the 7MM was approximately USD 3,726 million in 2022 and is projected to reach nearly USD 5,874 million by 2036.

• The United States accounted for the highest Acute Liver Failure treatment market size in 2025 compared to EU4 countries, the United Kingdom, and Japan.

• ALF is a rare yet life-threatening condition, with approximately 3,000 cases reported annually in North America, accounting for nearly 4–5% of all liver transplants.

• Drug-induced liver injury (DILI) was found to be responsible for nearly 50% of ALF cases in the US, with acetaminophen toxicity being the leading cause.

• In the UK, paracetamol toxicity accounts for nearly 65% of ALF cases.

• In Japan, hepatitis B virus infection is the primary cause of ALF, responsible for approximately 40% of cases.

• In Germany, the incidence of ALF was estimated at 1.22 per 100,000 person-years, with females accounting for 53% of cases.

• Leading Acute Liver Failure companies, such as SeaBeLife and bit.bio, are developing emerging ALF therapies to address the high unmet need in this space.

• The promising Acute Liver Failure therapies in development include SBL01 and bbHEP01.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/acute-liver-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Acute Liver Failure MarketRising Incidence of Drug-Induced Liver Injury and Acetaminophen Toxicity

Drug-induced liver injury remains the leading cause of Acute Liver Failure globally. Increasing use of prescription medications, over-the-counter drugs, dietary supplements, and substance abuse contribute significantly to the rising burden of ALF cases.

Increasing Burden of Viral Hepatitis-Associated ALF

Viral hepatitis, especially hepatitis B, continues to contribute substantially to ALF incidence in several regions, particularly Japan and developing countries, thereby driving demand for improved therapeutic management.

Growing Need for Effective Disease-Modifying Therapies

Currently, no approved targeted pharmacological therapies are available for ALF. Management primarily relies on supportive care and liver transplantation, highlighting the urgent need for novel regenerative and hepatoprotective therapies.

Advancements in Critical Care and Liver Support Systems

Improvements in intensive care management, intracranial pressure management, liver support systems, and transplantation protocols are enhancing patient survival and expanding treatment access.

Acute Liver Failure Competitive Landscape

• Several companies are evaluating novel approaches for Acute Liver Failure treatment, including SeaBeLife and bit.bio.

• The emerging ALF therapies include SBL01 and bbHEP01.

• SBL01 is a first-in-class small molecule designed to inhibit necroptosis and ferroptosis, thereby protecting hepatocytes and supporting liver regeneration.

• bbHEP01 utilizes encapsulated allogeneic hepatocyte-like cells developed using cell programming technology to provide temporary liver support and bridge patients to transplantation or spontaneous liver recovery.

Discover more about therapies set to grab major Acute Liver Failure market share @ Acute Liver Failure Treatment Landscape

Recent Developments in the Acute Liver Failure Market

• In September 2024, the EMA granted orphan drug designation to SeaBeLife’s SBL01 for the treatment of Acute Liver Failure.

• bit.bio announced that bbHEP01 is expected to initiate clinical trials in 2025, with preliminary clinical results anticipated in 2026.

• The ALF treatment pipeline remains limited, highlighting substantial opportunities for innovation and development of disease-modifying therapies.

What is Acute Liver Failure?

Acute Liver Failure (ALF), also known as fulminant hepatic failure, is characterized by the sudden onset of severe liver dysfunction due to rapid liver cell death or injury in patients without preexisting liver disease. The American Association for the Study of Liver Diseases (AASLD) defines ALF as the presence of coagulation abnormalities, usually an international normalized ratio (INR) above 1.5, along with any degree of hepatic encephalopathy occurring within less than 26 weeks of illness onset.

ALF may result from multiple causes including acetaminophen overdose, drug-induced liver injury, viral hepatitis, autoimmune hepatitis, Wilson’s disease, vascular injury, and metabolic disorders. Symptoms often begin with fatigue, nausea, vomiting, and abdominal discomfort, followed by jaundice, encephalopathy, cerebral edema, coagulopathy, and multiorgan failure.

Acute Liver Failure Epidemiology Segmentation

The Acute Liver Failure epidemiology section provides insights into the historical and current ALF patient pool and forecasted trends for the leading markets. The Acute Liver Failure market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

• Total Incident Cases of Acute Liver Failure

• Gender-specific Cases of Acute Liver Failure

• Age-specific Cases of Acute Liver Failure

• Etiology-specific Cases of Acute Liver Failure

• Treated Cases of Acute Liver Failure

Scope of the Acute Liver Failure Market Report

• Therapeutic Assessment: Acute Liver Failure current and emerging therapies

• Acute Liver Failure Market Dynamics: Key Market Forecast Assumptions and Market Outlook

• Key Companies: SeaBeLife, bit.bio, and others

• Key Therapies: SBL01, bbHEP01, N-acetylcysteine (NAC), supportive care therapies, and others

• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

• Unmet Needs, KOL’s views, Analyst’s views, Acute Liver Failure Market Access and Reimbursement

To know more about Acute Liver Failure companies working in the treatment market, visit @ Acute Liver Failure Clinical Trials and Therapeutic Assessment

Table of Contents

1. Acute Liver Failure Market Report Introduction

2. Executive Summary for Acute Liver Failure

3. SWOT Analysis of Acute Liver Failure

4. Acute Liver Failure Patient Share (%) Overview at a Glance

5. Acute Liver Failure Market Overview at a Glance

6. Acute Liver Failure Background and Overview

7. Acute Liver Failure Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Liver Failure

9. Acute Liver Failure Current Treatment and Medical Practices

10. Acute Liver Failure Unmet Needs

11. Acute Liver Failure Emerging Therapies

12. Acute Liver Failure Market Outlook

13. Country-Wise Acute Liver Failure Market Analysis (2022–2036)

14. Acute Liver Failure Market Access and Reimbursement of Therapies

15. Acute Liver Failure Market Drivers

16. Acute Liver Failure Market Barriers

17. Acute Liver Failure Appendix

18. Acute Liver Failure Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services